BiotechTube

VXA-A1.1 H1 Tablet Vaccine (small) + VXA-A1.1 H1 Tablet Vaccine (large)

Phase 1Completed
0 views this week 0 watching💤 Quiet
Interest: 19/100
19
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Seasonal Influenza Preventative Vaccine Pharmacodynamics

Conditions

Seasonal Influenza Preventative Vaccine Pharmacodynamics

Trial Timeline

Mar 31, 2017 → Apr 3, 2018

NCT ID
NCT03121339

About VXA-A1.1 H1 Tablet Vaccine (small) + VXA-A1.1 H1 Tablet Vaccine (large)

VXA-A1.1 H1 Tablet Vaccine (small) + VXA-A1.1 H1 Tablet Vaccine (large) is a phase 1 stage product being developed by Vaxart for Seasonal Influenza Preventative Vaccine Pharmacodynamics. The current trial status is completed. This product is registered under clinical trial identifier NCT03121339. Target conditions include Seasonal Influenza Preventative Vaccine Pharmacodynamics.

What happened to similar drugs?

20 of 20 similar drugs in Seasonal Influenza Preventative Vaccine Pharmacodynamics were approved

Approved (20) Terminated (0) Active (0)
✅montelukastMerckApproved
✅Cell-derived influenza vaccine + Egg-derived influenza vaccineNovartisApproved
✅KetotifenNovartisApproved
✅Fexofenadine HClSanofiApproved
✅Placebo nasal spray + Triamcinolone acetonide aqueous (TAA-AQ) nasal spray (NASACORT AQ) + Placebo nasal spray + Claritin® SyrupSanofiApproved
✅fexofenadine HClSanofiApproved
✅levocetirizine dihydrochlorideUCBApproved

Hype Score Breakdown

Clinical
6
Activity
8
Company
5
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT03121339Phase 1Completed

Competing Products

20 competing products in Seasonal Influenza Preventative Vaccine Pharmacodynamics

See all competitors
ProductCompanyStageHype Score
mRNA-1273ModernaPhase 1
0
mRNA-1010ModernaPhase 3
0
mRNA-1011.1ModernaPhase 2
0
mRNA-1010ModernaPhase 3
0
mRNA-1010ModernaPhase 3
0
mRNA-1030ModernaPhase 2
0
mRNA-1010ModernaPhase 2
0
mRNA-1010ModernaPhase 3
0
Bilastine + Desloratadine + PlaceboYuhanPhase 3
40
ASP4070 + PlaceboAstellas PharmaPhase 2
35
S-555739 Dose 1 + S-555739 Dose 2 + Cetirizine HCl Dose 1 + S-555739 placebo + Cetirizine HCl placeboShionogiPhase 2
35
Cetirizine + High dose ONO-4053 + Low dose ONO-4053 + PlaceboOno PharmaceuticalPhase 2
35
Ciclesonide nasal aerosol 37 mcg + ciclesonide nasal aerosol 74 mcg + PlaceboSumitomo PharmaPhase 3
40
80 mcg Ciclesonide + 160 mcg Ciclesonide + PlaceboSumitomo PharmaPhase 3
40
Ciclesonide HFA 160 μg + Ciclesonide HFA 80 μg + PlaceboSumitomo PharmaPhase 3
40
GSP 301-1 NS (QD) + GSP 301-2 NS (BID) + GSP 301 Placebo NS + Olopatadine HCl-1 NS (QD) + Olopatadine HCl-2 NS (BID) + Mometasone Furoate-1 NS (QD) + Mometasone Furoate-2 NS (BID)Glenmark PharmaceuticalsPhase 2
35
Molo 1 (also referred as GSP 301-2 NS) + Molo 2 (also referred as GSP 301-1 NS) + Placebo nasal spray + DYMISTA nasal spray + PATANASE nasal sprayGlenmark PharmaceuticalsPhase 2
35
JNJ38224342 + JNJ38224342/placebo + JNJ38224342/placebo + JNJ38224342/placeboJohnson & JohnsonPhase 1
29
Ciclesonide + PlaceboAstraZenecaPhase 3
40
Ciclesonide + PlaceboAstraZenecaPhase 3
40